AEON Biopharma Faces Delisting Concerns
Ticker: AEON · Form: 8-K · Filed: Apr 25, 2025 · CIK: 1837607
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
AEON Biopharma might get delisted - big trouble ahead.
AI Summary
AEON Biopharma, Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as Priveterra Acquisition Corp., is incorporated in Delaware and has its principal executive offices in Irvine, California.
Why It Matters
This filing indicates potential issues with AEON Biopharma's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ongoing operations and stock viability.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- April 22, 2025 (date) — Earliest event reported
- April 25, 2025 (date) — Date of report
- Irvine, CA (location) — Principal executive offices
FAQ
What specific listing rule or standard has AEON Biopharma failed to satisfy?
The filing does not specify the exact rule or standard that AEON Biopharma has failed to satisfy, only that a notice has been received.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated April 22, 2025.
What was AEON Biopharma's former company name?
AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp.
Where are AEON Biopharma's principal executive offices located?
AEON Biopharma's principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What is the SIC code for AEON Biopharma, Inc.?
The Standard Industrial Classification (SIC) code for AEON Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 25, 2025 regarding AEON Biopharma, Inc. (AEON).